CU24609B1 - Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic - Google Patents
Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de micInfo
- Publication number
- CU24609B1 CU24609B1 CU2018000050A CU20180050A CU24609B1 CU 24609 B1 CU24609 B1 CU 24609B1 CU 2018000050 A CU2018000050 A CU 2018000050A CU 20180050 A CU20180050 A CU 20180050A CU 24609 B1 CU24609 B1 CU 24609B1
- Authority
- CU
- Cuba
- Prior art keywords
- protein
- domain
- ferritin subunit
- fusion protein
- linked
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 101710157275 Ferritin subunit Proteins 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
<p>La presente invención proporciona una proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de MIC, en donde la proteína de subunidad de ferritina monomérica comprende un dominio que permite que la proteína de fusión se autoensamble en nanopartículas, y en donde la proteína de dominio alfa 3 de MIC comprende un péptido que consiste de la secuencia de aminoácidos de SEQ ID NO:3 o SEQ ID NO:4 o una secuencia que es al menos 90 % idéntica a las mismas; nanopartícula que comprende dicha proteína de fusión y una composición de vacuna que comprende dicha nanopartícula.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263377P | 2015-12-04 | 2015-12-04 | |
| US201662422454P | 2016-11-15 | 2016-11-15 | |
| PCT/US2016/064969 WO2017096374A1 (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180050A7 CU20180050A7 (es) | 2018-11-06 |
| CU24609B1 true CU24609B1 (es) | 2022-06-06 |
Family
ID=57590885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000061A CU20210061A7 (es) | 2015-12-04 | 2016-12-05 | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer |
| CU2018000050A CU24609B1 (es) | 2015-12-04 | 2016-12-05 | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000061A CU20210061A7 (es) | 2015-12-04 | 2016-12-05 | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10993971B2 (es) |
| EP (1) | EP3383426A1 (es) |
| JP (2) | JP7099956B2 (es) |
| KR (1) | KR20180088458A (es) |
| CN (1) | CN108770343A (es) |
| AU (2) | AU2016362597C1 (es) |
| BR (1) | BR112018010705A8 (es) |
| CA (1) | CA3005910A1 (es) |
| CL (3) | CL2018001470A1 (es) |
| CO (1) | CO2018006642A2 (es) |
| CR (2) | CR20230116A (es) |
| CU (2) | CU20210061A7 (es) |
| EA (1) | EA201891287A1 (es) |
| IL (1) | IL259490A (es) |
| MX (2) | MX2018006785A (es) |
| MY (1) | MY199248A (es) |
| NZ (1) | NZ742663A (es) |
| PE (2) | PE20181158A1 (es) |
| PH (1) | PH12018501170A1 (es) |
| RU (2) | RU2747296C2 (es) |
| SG (1) | SG11201804597TA (es) |
| TN (1) | TN2018000187A1 (es) |
| WO (1) | WO2017096374A1 (es) |
| ZA (1) | ZA202204223B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021519597A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| JP2021519599A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | 抗原性ｏｓｐａポリペプチド |
| WO2019195316A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Ferritin proteins |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| CN116396398B (zh) * | 2023-01-16 | 2024-07-16 | 四川大学 | 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| DE69737125T3 (de) | 1996-10-31 | 2015-02-26 | Human Genome Sciences, Inc. | Streptococcus pneumoniae-Antigene und Impfstoffe |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
| AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| CA2776391C (en) | 2001-10-01 | 2015-03-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| US6706305B2 (en) | 2001-10-31 | 2004-03-16 | Conagra Foods Inc. | Low glycemic index bread |
| CN1659187A (zh) | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | 融合铁蛋白在疫苗和其他方面的应用 |
| US20090104170A1 (en) | 2004-11-02 | 2009-04-23 | Richard William Wyatt Childs | Compositions and methods for treating hyperproliferative disorders |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| CA2665090A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating mica-related disorders |
| WO2011046842A1 (en) | 2009-10-12 | 2011-04-21 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| WO2011074573A1 (ja) | 2009-12-18 | 2011-06-23 | 花王株式会社 | メソポーラスシリカ粒子の製造方法 |
| JP5603063B2 (ja) | 2009-12-21 | 2014-10-08 | 花王株式会社 | 複合シリカ粒子の製造方法 |
| RU2489169C2 (ru) * | 2010-10-12 | 2013-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Способ лечения онкологических заболеваний |
| WO2013041966A1 (en) * | 2011-09-23 | 2013-03-28 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
| AU2012315792B2 (en) | 2011-09-30 | 2017-09-07 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| EP2812027A1 (en) | 2012-02-07 | 2014-12-17 | Innate Pharma | Mica binding agents |
| DK2838515T3 (da) | 2012-04-16 | 2020-02-24 | Harvard College | Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser |
| JP6518199B6 (ja) | 2013-03-15 | 2019-06-12 | ノヴェロジックス・バイオテクノロジー，インコーポレーテッド | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| NZ629816A (en) | 2013-03-15 | 2017-07-28 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| CN106456728A (zh) * | 2014-03-14 | 2017-02-22 | 达纳－法伯癌症研究所公司 | 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法 |
-
2016
- 2016-12-05 MY MYPI2018000849A patent/MY199248A/en unknown
- 2016-12-05 PE PE2018001072A patent/PE20181158A1/es unknown
- 2016-12-05 CU CU2021000061A patent/CU20210061A7/es unknown
- 2016-12-05 KR KR1020187019140A patent/KR20180088458A/ko not_active Application Discontinuation
- 2016-12-05 CN CN201680080434.4A patent/CN108770343A/zh active Pending
- 2016-12-05 SG SG11201804597TA patent/SG11201804597TA/en unknown
- 2016-12-05 CA CA3005910A patent/CA3005910A1/en active Pending
- 2016-12-05 NZ NZ742663A patent/NZ742663A/en unknown
- 2016-12-05 CU CU2018000050A patent/CU24609B1/es unknown
- 2016-12-05 WO PCT/US2016/064969 patent/WO2017096374A1/en active Application Filing
- 2016-12-05 JP JP2018528691A patent/JP7099956B2/ja active Active
- 2016-12-05 EA EA201891287A patent/EA201891287A1/ru unknown
- 2016-12-05 CR CR20230116A patent/CR20230116A/es unknown
- 2016-12-05 MX MX2018006785A patent/MX2018006785A/es unknown
- 2016-12-05 TN TNP/2018/000187A patent/TN2018000187A1/en unknown
- 2016-12-05 US US15/781,448 patent/US10993971B2/en active Active
- 2016-12-05 EP EP16816550.4A patent/EP3383426A1/en active Pending
- 2016-12-05 PE PE2022002801A patent/PE20230495A1/es unknown
- 2016-12-05 BR BR112018010705A patent/BR112018010705A8/pt active Search and Examination
- 2016-12-05 AU AU2016362597A patent/AU2016362597C1/en active Active
- 2016-12-05 RU RU2018123307A patent/RU2747296C2/ru active
- 2016-12-05 RU RU2021109510A patent/RU2021109510A/ru unknown
- 2016-12-05 CR CR20180350A patent/CR20180350A/es unknown
-
2018
- 2018-05-21 IL IL259490A patent/IL259490A/en unknown
- 2018-06-01 PH PH12018501170A patent/PH12018501170A1/en unknown
- 2018-06-01 MX MX2022010194A patent/MX2022010194A/es unknown
- 2018-06-01 CL CL2018001470A patent/CL2018001470A1/es unknown
- 2018-06-27 CO CONC2018/0006642A patent/CO2018006642A2/es unknown
-
2021
- 2021-02-19 US US17/180,183 patent/US20210299186A1/en not_active Abandoned
- 2021-05-13 CL CL2021001256A patent/CL2021001256A1/es unknown
-
2022
- 2022-03-21 AU AU2022201940A patent/AU2022201940A1/en active Pending
- 2022-04-14 ZA ZA2022/04223A patent/ZA202204223B/en unknown
- 2022-06-30 JP JP2022105405A patent/JP7564842B2/ja active Active
-
2023
- 2023-10-26 CL CL2023003217A patent/CL2023003217A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24609B1 (es) | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic | |
| CO2018000303A2 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| UA118167C2 (uk) | Пептид та його застосування | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| ES2691091T3 (es) | Vacuna conjugada de péptido antigénico de WT1 | |
| CY1119149T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
| PE20151978A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo | |
| EA201390820A1 (ru) | Слитый белок против рака | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| EP3360895A3 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| CY1125143T1 (el) | Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων | |
| BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
| AR119056A2 (es) | Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada |